MDRNA Narrows Pipeline to Focus Exclusively on Liver Cancer, Inks Licensing Deal with Novartis
March 26, 2009
MDRNA Narrows Pipeline to Focus Exclusively on Liver Cancer, Inks Licensing Deal with Novartis
MDRNA also reported its fourth-quarter financial results, posting lower operating costs on the elimination of non-RNAi programs and operations the company was working on prior to a corporate reorganization.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Three RNAi, miRNA Firms Record Strong Gains in Stock Value Since the End of 2008
April 30, 2009 / Gene Silencing News - Strands
February 19, 2009 / Gene Silencing News - Tekmira Delays Start of Cancer Drug Trial, Sees Expanded Roche Partnership in '09
March 26, 2009 / Gene Silencing News - RXi Names Inflammatory Disease as Lead Program; Neurological Disease Slips Off Radar
March 26, 2009 / Gene Silencing News - UMMS Team Publishes In Vitro, In Vivo Data on Oral siRNA-Delivery Tech
April 30, 2009 / Gene Silencing News